Magnetic Resonance Spectroscopy in Common Dementias

Neuroimaging Clinics of North America

Volumn 23, Issue 3, 2013, Pages 393-406

  Kantarci, Kejal ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Dementias; Magnetic resonance spectroscopy; Mild cognitive impairment; N Acetylaspartate

Indexed keywords

CHOLINESTERASE INHIBITOR; INOSITOL; N ACETYLASPARTIC ACID; PLACEBO;

ALZHEIMER DISEASE; BRAIN LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GENETIC ASSOCIATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RESTING STATE NETWORK; REVIEW; STANDARDIZATION; TREATMENT RESPONSE;

EID: 84881374066     PISSN: 10525149     EISSN: 15579867     Source Type: Journal    
DOI: 10.1016/j.nic.2012.10.004     Document Type: Review

References (134)

1. Brown G.G., Levine S.R., Gorell J.M., et al. Invivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989, 39(11):1423-1427.
2. Pettegrew J.W., Moossy J., Withers G., et al. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. JNeuropathol Exp Neurol 1988, 47(3):235-248.
3. Pettegrew J.W., Panchalingam K., Moossy J., et al. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Arch Neurol 1988, 45(10):1093-1096.
4. Klunk W.E., Panchalingam K., Moossy J., et al. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 1992, 42(8):1578-1585.
5. Miller B.L., Moats R.A., Shonk T., et al. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993, 187(2):433-437.
6. Huang W., Alexander G.E., Chang L., et al. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 2001, 57(4):626-632.
7. Jessen F., Block W., Traber F., et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000, 55(5):684-688.
8. Kantarci K., Jack C.R., Xu Y.C., et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000, 55(2):210-217.
9. Meyerhoff D.J., MacKay S., Constans J.M., et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by invivo proton magnetic resonance spectroscopic imaging. Ann Neurol 1994, 36(1):40-47.
10. Moats R.A., Ernst T., Shonk T.K., et al. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994, 32(1):110-115.
11. Mohanakrishnan P., Fowler A.H., Vonsattel J.P., et al. Regional metabolic alterations in Alzheimer's disease: an invitro 1H NMR study of the hippocampus and cerebellum. JGerontol A Biol Sci Med Sci 1997, 52(2):B111-B117.
12. Pfefferbaum A., Adalsteinsson E., Spielman D., et al. Invivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 1999, 41(2):276-284.
13. Rose S.E., de Zubicaray G.I., Wang D., et al. A1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 1999, 17(2):291-299.
14. Schuff N., Capizzano A.A., Du A.T., et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002, 58(6):928-935.
15. Shonk T., Ross B.D. Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med 1995, 33(6):858-861.
16. Rai G.S., McConnell J.R., Waldman A., et al. Brain proton spectroscopy in dementia: an aid to clinical diagnosis. Lancet 1999, 353(9158):1063-1064.
17. Christiansen P., Toft P., Larsson H.B., et al. The concentration of N-acetyl aspartate, creatine+ phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging 1993, 11(6):799-806.
18. Ernst T., Chang L., Melchor R., et al. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997, 203(3):829-836.
19. Parnetti L., Tarducci R., Presciutti O., et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997, 97(1):9-14.
20. Schuff N., Amend D., Ezekiel F., et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997, 49(6):1513-1521.
21. Shonk T.K., Moats R.A., Gifford P., et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995, 195(1):65-72.
22. Antuono P.G., Jones J.L., Wang Y., et al. Decreased glutamate+ glutamine in Alzheimer's disease detected invivo with (1)H-MRS at 0.5 T. Neurology 2001, 56(6):737-742.
23. Hattori N., Abe K., Sakoda S., et al. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002, 13(1):183-186.
24. Tedeschi G., Bertolino A., Lundbom N., et al. Cortical and subcortical chemical pathologic conditions in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 1996, 47(3):696-704.
25. Schuff N., Amend D.L., Meyerhoff D.J., et al. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 1998, 207(1):91-102.
26. Zhu X., Schuff N., Kornak J., et al. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord 2006, 20(2):77-85.
27. Frederick B.B., Satlin A., Yurgelun-Todd D.A., et al. Invivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol Psychiatry 1997, 42(2):147-150.
28. Kwo-On-Yuen P.F., Newmark R.D., Budinger T.F., et al. Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study. Brain Res 1994, 667(2):167-174.
29. Chantal S., Braun C.M., Bouchard R.W., et al. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004, 1003(1-2):26-35.
30. Kantarci K., Smith G.E., Ivnik R.J., et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. JInt Neuropsychol Soc 2002, 8(7):934-942.
31. Sweet R.A., Panchalingam K., Pettegrew J.W., et al. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathologic conditions. Neurobiol Aging 2002, 23(4):547-553.
32. Shinno H., Inagaki T., Miyaoka T., et al. Adecrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. JNeurol Sci 2007, 260(1-2):132-138.
33. Jessen F., Gur O., Block W., et al. Amulticenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 2009, 72(20):1735-1740.
34. Kantarci K., Reynolds G., Petersen R.C., et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol 2003, 24(5):843-849.
35. Rupsingh R., Borrie M., Smith M., et al. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 2011, 32(5):802-810.
36. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239-259.
37. Minoshima S. Imaging Alzheimer's disease: clinical applications. Neuroimaging Clin N Am 2003, 13(4):769-780.
38. Reiman E.M., Caselli R.J., Yun L.S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. NEngl J Med 1996, 334(12):752-758. [see comment].
39. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008, 1124:1-38.
40. Chen S.Q., Wang P.J., Ten G.J., et al. Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Disord 2009, 28(6):558-566.
41. Cheng L.L., Newell K., Mallory A.E., et al. Quantification of neurons in Alzheimer and control brains with exvivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn Reson Imaging 2002, 20(7):527-533.
42. Dedeoglu A., Choi J.K., Cormier K., et al. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 2004, 1012(1-2):60-65.
43. Marjanska M., Curran G.L., Wengenack T.M., et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 2005, 102(33):11906-11910.
44. von Kienlin M., Kunnecke B., Metzger F., et al. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 2005, 18(1):32-39.
45. Sailasuta N., Harris K., Tran T., et al. Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study. Neuropsychiatr Dis Treat 2011, 7:495-499.
46. Kantarci K., Knopman D.S., Dickson D.W., et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008, 248(1):210-220.
47. Adalsteinsson E., Sullivan E.V., Kleinhans N., et al. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000, 355(9216):1696-1697.
48. Kantarci K., Weigand S.D., Petersen R.C., et al. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007, 28(9):1330-1339.
49. Schott J.M., Frost C., MacManus D.G., et al. Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. Brain 2010, 133(11):3315-3322.
50. Jessen F., Block W., Traber F., et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001, 57(5):930-932.
51. Traber F., Block W., Freymann N., et al. Amulticenter reproducibility study of single-voxel 1H-MRS of the medial temporal lobe. Eur Radiol 2006, 16(5):1096-1103.
52. Okada T., Sakamoto S., Nakamoto Y., et al. Reproducibility of magnetic resonance spectroscopy in correlation with signal-to-noise ratio. Psychiatry Res 2007, 156(2):169-174.
53. Modrego P.J., Fayed N., Errea J.M., et al. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 2010, 17(3):405-412.
54. Krishnan K.R., Charles H.C., Doraiswamy P.M., et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003, 160(11):2003-2011.
55. Modrego P.J., Pina M.A., Fayed N., et al. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 2006, 20(10):867-877.
56. Penner J., Rupsingh R., Smith M., et al. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(1):104-110.
57. Bartha R., Smith M., Rupsingh R., et al. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(3):786-793.
58. McKeith I.G., Dickson D.W., Lowe J., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65(12):1863-1872.
59. Hamilton R.L. Lewy bodies in Alzheimer's disease:a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000, 10(3):378-384.
60. Gomez-Isla T., Growdon W.B., McNamara M., et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999, 53(9):2003-2009.
61. Kantarci K., Petersen R.C., Boeve B.F., et al. 1H MR spectroscopy in common dementias. Neurology 2004, 63(8):1393-1398.
62. Xuan X., Ding M., Gong X. Proton magnetic resonance spectroscopy detects a relative decrease of N-acetylaspartate in the hippocampus of patients with dementia with Lewy bodies. JNeuroimaging 2008, 18(2):137-141.
63. Kantarci K., Ferman T.J., Boeve B.F., et al. Focal Atrophy on MRI and neuropathologic classification of dementia with lewy bodies. Neurology 2012, 79(6):553-560.
64. Molina J.A., Garcia-Segura J.M., Benito-Leon J., et al. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol 2002, 48(3):158-163.
65. Firbank M.J., Blamire A.M., Krishnan M.S., et al. Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease. Psychiatry Res 2007, 155(2):135-145.
66. Kantarci K., Avula R., Senjem M.L., et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology 2010, 74(22):1814-1821.
67. Tiraboschi P., Hansen L.A., Alford M., et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002, 59(10):946-951.
68. McKeith I.G., Grace J.B., Walker Z., et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000, 15(5):387-392.
69. Satlin A., Bodick N., Offen W.W., et al. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 1997, 154(10):1459-1461.
70. Holmes C., Cairns N., Lantos P., et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999, 174:45-50.
71. Schneider J.A., Arvanitakis Z., Bang W., et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69(24):2197-2204.
72. Kattapong V.J., Brooks W.M., Wesley M.H., et al. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch Neurol 1996, 53(7):678-680.
73. MacKay S., Meyerhoff D.J., Constans J.M., et al. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996, 53(2):167-174.
74. Ross A.J., Sachdev P.S., Wen W., et al. 1H MRS in stroke patients with and without cognitive impairment. Neurobiol Aging 2005, 26(6):873-882.
75. Waldman A.D., Rai G.S., McConnell J.R., et al. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr 2002, 35(2):137-142.
76. Shiino A., Watanabe T., Shirakashi Y., et al. The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy. JCereb Blood Flow Metab 2012, 32(5):805-815.
77. Garrard P., Schott J.M., MacManus D.G., et al. Posterior cingulate neurometabolite profiles and clinicalphenotype in frontotemporal dementia. Cogn Behav Neurol 2006, 19(4):185-189.
78. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol 2007, 80(Spec No 2):S146-S152.
79. Mihara M., Hattori N., Abe K., et al. Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. Neuroreport 2006, 17(4):413-416.
80. Boeve B.F., Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 2008, 65(4):460-464.
81. Hutton M., Lendon C.L., Rizzu P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393(6686):702-705.
82. Rademakers R., Cruts M., van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 2004, 24(4):277-295.
83. Foster N.L., Wilhelmsen K., Sima A.A., et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference participants. Ann Neurol 1997, 41(6):706-715.
84. Ingram D.A., Wenning M.J., Shannon K., et al. Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood 2003, 101(5):1984-1986.
85. Whitwell J.L., Jack C.R., Boeve B.F., et al. Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 2009, 72(9):813-820.
86. Bunker J.M., Kamath K., Wilson L., et al. FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. JBiol Chem 2006, 281(17):11856-11863.
87. Sperling R.A., Jack C.R., Aisen P.S. Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3(111):111cm133.
88. Thal L.J., Kantarci K., Reiman E.M., et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20(1):6-15.
89. Petersen R.C., Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58(12):1985-1992.
90. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):280-292.
91. Petersen R.C. Mild cognitive impairment as a diagnostic entity. JIntern Med 2004, 256(3):183-194.
92. Bennett D.A., Wilson R.S., Schneider J.A., et al. Natural history of mild cognitive impairment in older persons. Neurology 2002, 59(2):198-205.
93. Bowen J., Teri L., Kukull W., et al. Progression to dementia in patients with isolated memory loss. Lancet 1997, 349(9054):763-765.
94. Flicker C., Ferris S.H., Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991, 41(7):1006-1009.
95. Jicha G.A., Parisi J.E., Dickson D.W., et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006, 63(5):674-681.
96. Meyer J.S., Xu G., Thornby J., et al. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease?. Stroke 2002, 33(8):1981-1985.
97. Morris J.C., Storandt M., Miller J.P., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001, 58(3):397-405.
98. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56(3):303-308. [Erratum appears in Arch Neurol 1999;56(6):760].
99. Kantarci K., Petersen R.C., Przybelski S.A., et al. Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 2008, 65(12):1621-1628.
100. Mariani E., Monastero R., Ercolani S., et al. Vascular risk factors in mild cognitive impairment subtypes. Findings from the ReGAl project. Dement Geriatr Cogn Disord 2007, 24(6):448-456.
101. Bennett D.A., Schneider J.A., Bienias J.L., et al. Mild cognitive impairment is related to Alzheimer disease pathologic conditions and cerebral infarctions. Neurology 2005, 64(5):834-841.
102. Petersen R.C., Parisi J.E., Dickson D.W., et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006, 63(5):665-672.
103. Schneider J.A., Arvanitakis Z., Leurgans S.E., et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009, 66(2):200-208.
104. Molano J., Boeve B., Ferman T., et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010, 133(Pt 2):540-556.
105. Busse A., Hensel A., Guhne U., et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006, 67(12):2176-2185.
106. Fischer P., Jungwirth S., Zehetmayer S., et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007, 68(4):288-291.
107. Catani M., Cherubini A., Howard R., et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001, 12(11):2315-2317.
108. Chao L.L., Schuff N., Kramer J.H., et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 2005, 64(2):282-289.
109. Barkhof F., Polvikoski T.M., van Straaten E.C., et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007, 69(15):1521-1527.
110. Bobinski M., Wegiel J., Tarnawski M., et al. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. JNeuropathol Exp Neurol 1997, 56(4):414-420.
111. Gosche K.M., Mortimer J.A., Smith C.D., et al. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002, 58(10):1476-1482.
112. Jack C.R., Dickson D.W., Parisi J.E., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58(5):750-757.
113. Zarow C., Vinters H.V., Ellis W.G., et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol 2005, 57(6):896-903.
114. Jagust W.J., Zheng L., Harvey D.J., et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008, 63(1):72-80.
115. Kantarci K., Weigand S.D., Przybelski S.A., et al. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 2009, 72(17):1519-1525.
116. Jack C.R., Petersen R.C., Xu Y.C., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52(7):1397-1403.
117. Martinez-Bisbal M.C., Arana E., Marti-Bonmati L., et al. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol 2004, 11(3):187-193.
118. Metastasio A., Rinaldi P., Tarducci R., et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 2006, 27(7):926-932.
119. Westman E., Wahlund L.O., Foy C., et al. Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. JAlzheimers Dis 2011, 26(Suppl 3):307-319.
120. Zimmerman M.E., Pan J.W., Hetherington H.P., et al. Hippocampal neurochemistry, neuromorphometry, and verbal memory in nondemented older adults. Neurology 2008, 70(18):1594-1600.
121. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):270-279.
122. Jack C.R., Albert M.S., Knopman D.S., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):257-262.
123. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):263-269.
124. Jack C.R., Knopman D.S., Jagust W.J., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9(1):119-128.
125. Huang W., Alexander G.E., Daly E.M., et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am J Psychiatry 1999, 156(12):1879-1886.
126. Godbolt A.K., Waldman A.D., MacManus D.G., et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006, 66(5):718-722.
127. Kantarci K., Boeve B.F., Wszolek Z.K., et al. MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathologic conditions. Neurology 2010, 75(9):771-778.
128. Brand A., Richter-Landsberg C., Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993, 15(3-5):289-298.
129. Urenjak J., Williams S.R., Gadian D.G., et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. JNeurosci 1993, 13(3):981-989.
130. Bitsch A., Bruhn H., Vougioukas V., et al. Inflammatory CNS demyelination: histopathologic correlation with invivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999, 20(9):1619-1627.
131. Dickson D.W. The pathogenesis of senile plaques. JNeuropathol Exp Neurol 1997, 56(4):321-339.
132. Ross B.D., Bluml S., Cowan R., et al. Invivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 1998, 8(4):809-822.
133. Kantarci K., Lowe V., Przybelski S.A., et al. Magnetic resonance spectroscopy, beta-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology 2011, 77(10):951-958.
134. Oz G., Nelson C.D., Koski D.M., et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. JNeurosci 2010, 30(10):3831-3838.